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Effect of Statin Therapy on Serum Lipase and Blood Glucose Levels in 
Patients with Hyperlipidemia 
Abstract 
Background: 
Hyperlipidemia is an abnormality in the lipoprotein metabolism that leads 
to alterations in the various lipoproteins and the prevalence was 37.5% in age 
group of 15 - 64 years. Hypercholesterolemia was identified to be the risk factor 
for coronary artery disease and cerobrovascular disease. Statins are the 
hypolipidemic drugs which helps in lowering the blood cholesterol and 
lipoprotein levels that acts by inhibiting the 3-Hydroxy-3-methyl glutaryl 
coenzyme A [HMG-CoA] reductase enzyme. Apart from various adverse effects 
mentioned in textbooks, there were case reports mentioning that statins can be a 
cause for the development of acute pancreatitis [AP], where there was an 
elevation in the levels of serum lipase, serum amylase and blood glucose. Hence 
it was hypothesized in this present study that, statin therapy in hyperlipidemic 
patients increases the levels of serum lipase and blood glucose.  
Aims and objectives:  
To evaluate the effect of statin therapy on serum lipase and blood glucose 
levels in hyperlipidemic patients. 
Materials and methods: 
This study included a total number of 71 participants who were diagnosed 
newly as hyperlipidemic and was advised as to start either on atorvastatin or 
rosuvastatin. The participants were explained about the study and consent was 
obtained from each participant for collection of 3 ml of blood for the estimation 
of serum lipase and blood glucose levels. The participants were advised to 
review after 3 months of therapy for estimation of serum lipase and blood 
glucose estimation. The study parameters are expressed in mean±Standard 
deviation. The P<0.05 was considered statistically significant.    
Results: 
    There was a significant increase in the serum lipase [P<0.0001] and blood 
glucose [P<0.0005] levels, after 3 months of statin therapy in hyperlipidemic 
patients.   
Conclusion: 
Three months of treatment with atorvastatin or rosuvastatin significantly 
increases the levels of serum lipase and blood glucose when compared with the 
base line. 
Key words: Pancreatitis, hyperglycemia, hyperlipasemia, blood glucose, serum 
lipase, hypercholesterolemia, statins, HMG-CoA reductase inhibitors.  
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1. Introduction 
 Abnormalities in the metabolism of lipoprotein can lead to 
hyperlipoproteinemia which causes alterations in the various lipoproteins.1 The 
prevalence of dyslipidemia in adult in the age group of 15 - 64 years was 37.5 % 
as reported by the Indian Council of Medical Research [ICMR] surveillance 
project.2 An epidemiological study have proved that there is a strong relationship 
between serum cholesterol levels and premature coronary artery disease [CAD].2 
Hypercholesterolemia has been identified as a risk factor for CAD3 and 
cerobrovascular disease [CVD]4 and the need for the intervention was 
established by the Framingham Heart Study in 1949 and 1961.3 CAD is the 
commonest cause for death and 25 % of the death that occurs in India was due to 
CAD in the year 1990.3 Hyperlipidemia is the most common cause of 
artherosclerosis of the blood vessel and these changes in the arteries to the 
central nervous system leads to CVD like strokes and transient cerebral 
ischaemia.5 
Statins are a group of hypolipidemic drugs which act by inhibiting the    
3-Hydroxy-3-methyl glutaryl coenzyme A [HMG-CoA] reductase enzyme.6 
These drugs help in lowering the blood cholesterol and lipoprotein levels. The 
use of hypolipidemic drugs has shown to reduce the atherosclerotic changes and 
thereby prevent cardiovascular disease in patients with hyperlipidemia.7 
 Lovastatin, fluvastatin, mevastatin, simvastatin, pravastatin, atorvastatin, 
rosuvastatin and pitavastatin are in HMG-CoA reductase inhibitors.6,7  
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Even though statins are well tolerated, they produce adverse drug 
reactions [ADRs] which includes myalgia, gastrointestinal [GI] disturbances, 
raised liver enzymes, insomnia and rash. More serious and rare adverse effects 
are rhabdomyolysis and angio-oedema.8 
 There were case reports published around the globe stating and 
confirming that statins can be a cause for the development of acute pancreatitis 
[AP] where there is elevation of serum lipase, serum amylase and blood glucose 
level.9-14 
The hypothesis of present study is that statin therapy in hyperlipidemic 
patients increases serum lipase and blood glucose levels. Based on case reports 
on statin induced pancreatitis9-14 it is assumed that there may be an impact on the 
pancreas which can lead to subclinical elevation in the levels of serum lipase and 
alteration in the blood glucose levels. 
Considering the burden, severity and mortality due to AP, an extensive 
review of literature showed that there were no similar studies done on the effect 
of statins on serum lipase and blood glucose levels in South India. Hence it was 
planned to evaluate the effect of statin therapy on serum lipase and blood glucose 
levels in hyperlipidemic patients. 
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2. Aims and Objectives: 
To evaluate the effect of statin therapy on serum lipase and blood glucose 
levels in hyperlipidemic patients. 
  
 
 
 
 
 
 
 
 
 
 
REVIEW OF 
LITERATURE 
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3. Review of Literature 
3.1. Lipids: 
 Lipids are biochemically important heterogeneous compounds that are 
water insoluble but are soluble in non-polar organic solvents.15 They are 
transported in plasma in lipoproteins which are complex larger macromolecules. 
Lipoproteins play a major role in the dietary cholesterol absorption.1 These 
lipoproteins can be visualized only by electron microscopy and separated by 
using ultracentrifugation.16 
3.1.1. Classification of lipoproteins: 
  They are classified depending upon the size, density and 
composition of the lipoproteins.17 
a) Chylomicrons 
b) Very low-density lipoproteins [VLDLs] 
c) Intermediate density lipoproteins [IDLs] 
d) Low-density lipoproteins [LDLs]  
e) High density lipoproteins [HDLs] 
3.1.1.1. Chylomicrons: 
 Chylomicrons are less dense lipoprotein with a density of 
<0.95g/ml and the largest among the lipoprotein. The proportion of 
various proteins in this includes apo B-48, apo A-I, apo A-II,  apo A-IV, 
apo C-II and  apo E. The Sf of more than 400 is considered as the largest 
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and Sf of 20-400 is designated as smaller chylomicrons. The chylomicron 
core predominantly consists of triglycerides and originates from the 
diet.16,17  
 Chylomicrons are synthesized and formed in the small intestine 
and then transported to the blood stream by lymphatics through the left 
subclavian vein. 
3.1.1.2. Very low density lipoproteins [VLDL]: 
 They are the largest lipoproteins which contain lipids that are 
endogenously produced with the density ranging from 0.95 to 1.006 
g/mL. The major component of VLDL is apo B-100 and it also includes 
apo C-I, apo C-II, apo C-III, apo E and apo A.17 
These are transported in the blood from the liver to the muscle and 
adipose tissue, where apo C-II activates the lipoprotein lipase leading to 
release of free fatty acids from VLDL.16 
3.1.1.3. Intermediate density lipoproteins [IDL]:17 
  The density of IDL ranges from 1.006 to 1.019 g/ml and are 
formed during the process of formation of low-density lipoprotein from 
very low-density lipoprotein. The intermediate-density lipoprotein core 
consists of cholesteryl esters and triglycerides. 
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3.1.1.4. Low density lipoprotein [LDL]:17 
Low density lipoproteins have cholesterol as the major part with 
the density ranging from 1.019 to 1.063 g/ml which contains lipoproteins 
and is the product that is formed at the end of the catabolism of very low 
density lipoprotein. The main protein component is apo B-100 and the 
low density lipoprotein core is formed of cholesteryl esters.  
Figure 1. Showing the density and formation of various lipoproteins by  
                 catabolism 
 
 
 
 
 
 
 
 
 
 
 
VLDL [0.95-1.006] 
IDL [1.006-1.019] 
LDL [1.019-1.063] 
Cholesteryl esters 
and triglycerides 
Apo B-100 
Cholesteryl esters 
Lipds 
Lipds 
Lipds 
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3.1.1.5. High density lipoprotein [HDL]: 
High density lipoprotein are smallest and the most dense 
lipoprotein lying between the range 1.063 to 1.210 g/mL.17 High density 
lipoproteins are rich in protein and is formed from the liver and small 
intestine.16  
They contain apo A-I alone, both apo A-I and apo A-II together or 
apo A-II alone, apo C-I, apo C-II and other apolipoproteins as well as 
lecithin cholesterol acyl transferase [LCAT] enzymes.16,17  
High density lipoproteins are sub classified depending upon the 
density and size as HDL2 and HDL3 and latter are smaller and denser than 
former.17  
During electrophoresis the alpha region attracts both HDL2 and 
HDL3. Lipid poor high density lipoproteins which are discoidal in shape 
migrates to the pre-β region during electrophoresis and they are also 
known as pre- β1 High density lipoprotein.17 These discoidal shaped 
pre-β1 HDL particles acquire cholesterol and forms a larger particle called 
as pre-β2 HDLs and is preferably the substrate for lecithin cholesterol 
acyltransferase.17 
3.1.2. Synthesis of cholesterol:18 
Cholesterol is a C27 steroid and is synthesized from acetyl coenzyme 
[CoA]. The first stage of cholesterol biosynthesis starts from three acetyl 
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CoA to form 3-hydroxy-3-methylglutaryl Coenzyme A. The conversion of 
3-hydroxy-3-methylglutaryl Coenzyme A to Mevalonic acid happens by 
reducing the thioester of 3-hydroxy-3-methylglutaryl Coenzyme A to 
primary hydroxyl group in the presence of 3-hydroxy-3-methylglutaryl 
Coenzyme A reductase enzyme which is the primary rate controlling enzyme 
in cholesterol synthesis. Mevalonic acid is then converted to isopentenyl 
pyrophosphate by successive phosphorylation and decarboxylation. 
The second stage of cholesterol biosynthesis is coupling of six 
molecules of isopentenyl pyrophosphate, of which three molecule of 
isopentenyl pyrophosphate condense to form a farnesyl pyrophosphate. Two 
molecule of farnesyl pyrophosphate thus formed forms a single squalene. 
The squalene thus formed initially undergoes epoxidation and cyclization to 
form lanosterol. 
The final stage is the formation of cholesterol from lanosterol by 
removal of three methyl group from lanosterol causing reduction of the side 
chain double bond and movement of other double bond within the ring 
structure. 
 The cholesterol biosynthesis is schematically presented in Figure 2. 
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Figure 2. Cholesterol Biosynthesis  
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3.1.3. Hyperlipidemia: 
Abnormalities in the metabolism of lipoprotein can lead to 
hyperlipidemia which causes alterations in the various lipoproteins.1 
Dyslipidemia is an important factor that predispose to early cerebrovascular 
disease [CVD] and coronary artery disease [CAD].19  
According to the National Commission on Macroeconomics and 
Health [NCMH] there will be approximately 62 million patients with 
coronary artery disease by 2015 and of these 23 million would be below the 
age group of 40 years.20 World Health Organization report 2002, has 
predicted that death due to coronary artery disease in India will be 2.6 
million by 2020.21 
Hyperlipidemias are classified as primary and secondary 
hyperlipidemias. Primary hyperlipidemia includes hypercholesterolemia and 
hypertriglyceridemia and is due to an inherent genetic defect of lipid-
lipoprotein-apoprotein metabolism.  
Secondary hyperlipidemia includes hypercholesterolemia and 
hypertriglyceridemia which are caused due to other underlying causes.22 
According to Indian Council of Medical Research [ICMR] surveillance 
project the prevalence of dyslipidemia among young male workers in 
industry was estimated to be 62 % whereas it was 37.5 % among the other 
population of age 15 - 64 years.2 
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3.1.3.1. Hypercholesterolemia:19 
Hypercholesterolemia is defined as the increased level of LDL and 
decrease in the HDL level and is associated with higher risk for 
development of morbidity and mortality due to CAD and CVD.  
3.1.3.2. Hypertriglyceridemia: 
Hypertriglyceridemia is a condition in which there will be an 
elevation in the triglyceride level and is associated with hyperlipidemias, 
type 2 diabetes mellitus [DM] and metabolic syndrome.23 Patients suffering 
from hypertriglyceridemia are often obese, hypertensive, insulin resistant or 
diabetic23 and are at high risk of developing CAD24 and acute pancreatitis.25 
3.1.4. Causes of hyperlipidemia: 
The underlying factors that lead to primary hyperlipidemia are genetic 
defects like polygenic hypercholesterolemia, decreased LDL clearance, 
primary clearance defect combined with secondary excess production of 
Triglyceride [TGL], familial combined hyperlipidemia, familial monogenic 
hypercholesterolaemia, familial deficiency of lipoprotein lipase [LPL], 
familial deficiency of apoprotein C11, familial endogenous 
hypertriglyceridemia  and familial type V hyperlipoproteinaemia.22 
The factors that cause secondary hyperlipidemia are hypothyroidism, 
hypopituitarism, diabetes mellitus [DM], glycogen storage disease, anorexia 
nervosa, bulimia, obesity, diets rich in saturated fat and carbohydrate, 
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excessive alcohol consumption, Cushing’s syndrome, nephrotic syndrome, 
cholestasis, acute intermittent porphyria, dysglobulinaemia, pancreatitis, 
chronic renal failure, chronic liver disease, intake of drugs like beta blockers, 
diuretics, glucocorticoids, oestrogens, oral contraceptive pill [OCP], or 
disease like  systemic lupus erythromatosis [SLE] and pregnancy.22 
Study conducted by García-Unciti et al.26 had revealed that life style 
changes like diet modification and exercise in hyperlipidemic patients had 
significantly decreased the weight and waist circumference as well as the 
serum levels of low-density lipoprotein [LDL] and total cholesterol [TCH]. 
De Goeij et al.27 in their study identified that there was an association 
between abnormal lipid levels and worsening of renal function in patients 
suffering from chronic kidney disease [CKD]. 
3.1.5. Normal lipid levels:28 
The third report of the National Cholesterol Education Program 
[NCEP] Adult Treatment Panel III [ATP III] on detection, evaluation, and 
treatment of high blood cholesterol in adults by the expert panel states that 
LDL cholesterol will be the primary target for therapy. 
According to the ATP III guidelines, all adults above the age of         
20 years should undergo evaluation of lipid profile once in 5 years. The 
normal value of lipid profile as suggested by National Cholesterol Education 
Program Adult Treatment Panel III [NCEP ATP III] is as follows, 
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Table 1. Normal values of various lipoproteins28 
PARAMETER NORMAL VALUE [mg/dl] 
Total Cholesterol < 200 
Triglycerides < 150 
Low Density Lipoprotein < 100 
High Density Lipoprotein 40 - 60 
 
3.1.6. Management of hyperlipidemia: 
Cardiovascular morbidity and mortality due to hyperlipidemia can be 
lowered by decreasing the LDL and TGL levels and by increasing the HDL 
levels.25 
Management of hyperlipidemia focuses on both non-
pharmacological29 and pharmacological approach.30 Non-pharmacological 
approach to decrease the morbidity and mortality due to hyperlipidemia 
includes diet modification with low-fat and low-carbohydrate31, physical 
activity for weight reduction,29, 32 smoking cessation and reduced alcohol 
consumption.29 
Kelly31 conducted a study on the effect of aerobic exercise in 
hyperlipidemic patients and had proved that it increased the HDL level by 
1.9 to 2.5 mg/dl on an average, decreased the TCH level by 3.9 mg/dl, LDL 
by 3.9 mg/dl and TGL level by 7.1 mg/dl. 
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Pharmacological agents for treating hyperlipidemia include statins, 
fibrates, nicotinic acid and bile acid sequestrants.25,30  
In addition fish oil, plant stanols and sterols and LDL apheresis have 
been used to effectively modify lipid levels.25,30 
The technique of apheresis for reducing the TGL level was first done 
in the year 1978 by Betteridge et al. and after that apheresis was considered 
as newer effective tool in the management of severe/extreme 
hypertriglyceridemia. Several studies had proven that management of 
severe/extreme hypertriglyceridemia with apheresis prevented the 
recurrence of acute pancreatitis and also reduced morbidity and mortality.23 
Fares et al.33 conducted a study with icosapent ethyl in severe 
hypertriglyceridemic patients and triglyceride level was found to be 
reduced. They also suggested that it can be used as an adjunct therapy to 
statins. Eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] are 
the two agents that form omega-3 fatty acid,34 where icosapent ethyl [IPE] 
is purest form of EPA.33,34 Icosapent ethyl was approved by the United 
States Food and Drug Administration [USFDA] as an adjunct therapy along 
with diet in severe hypertriglyceridemic patients.34 
A Multi-Centre, Placebo-Controlled, randomized, Double-Blind, 12-
week study with an open label Extension [MARINE] and Amarin’s Phase 3 
Clinical Trial [ANCHOR] revealed that icosapent ethyl significantly 
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reduced triglyceride [TGL], non-HDL, apolipoprotein B, VLDL-C and TC 
levels.34  
Ballantyne et al.35 stated that EPA 4 g/day and 2 g/day had 
significantly decreased TG, non-HDL cholesterol and LDL levels. 
Moreover it also decreased the apolipoprotein B levels. 
A pharmacokinetic study conducted by Braeckman et al.36 concluded 
that atorvastatin, a substrate of CYP3A4 did not have any clinically 
significant interactions with warfarin, rosiglitazone and omeprazole, which 
were substrates of CYP2C9, CYP2C8 and CYP2C19 respectively. It was 
also found that approved dose of icosapent ethyl at 4g/day had no effect on 
the single dose of atorvastatin in healthy individuals. 
Hovingh et al.37 conducted a randomized, double-blind, placebo-
controlled phase 2 trial with a new and novel cholesterol esterase transfer 
protein [CETP] inhibitor TA-8995 on 364 hyperlipidemic patients and have 
shown significant reduction in the LDL levels. 
Even though various groups of drugs were used, statins are considered 
to be the first line drugs for the treatment of hyperlipidemia.23 
3.2. Statins: 
3.2.1. History:6 
 Endo and colleagues identified statins as an inhibitor of cholesterol 
synthesis which were isolated from a mould, Penicillium citrinum in the 
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year 1976.  Further study conducted by Brown and Goldstein proved that 
statins inhibit the cholesterol synthesis by HMG-CoA reductase inhibition. 
Compactin was the first statin that was studied in human which was 
renamed later as mevastatin. The first approved statins for human use was 
developed by Alberts and colleagues at Merck laboratories and called as 
Lovastatin [formerly known as mevinolin] which was isolated from 
Aspergillus terreus. Pravastatin and simvastatin are semisynthetic where as 
atorvastatin, fluvastatin, rosuvastatin and pitavastatin are synthetic 
compounds.  
3.2.2. Introduction: 
Statins are the best tolerated and most effective drugs for the 
treatment of dyslipidemia. These drugs act by inhibiting the HMG-CoA 
reductase in the cholesterol biosynthesis.6,7 These drugs are helpful in the 
reduction of LDL38 and high dose of potent statins like atorvastatin, 
simvastatin and rosuvastatin also reduce the triglyceride level [TGL] caused 
by elevated VLDL levels.6,7 All statins except atorvastatin and rosuvastatin 
[plasma half life 18-24 hours] are advised to be taken at night due to the 
peak synthesis of hepatic cholesterol by HMG-CoA reductase which has 
maximum activity at midnight.6 
Statin therapy has shown to effectively reduce the cholesterol 
levels, which in turn reduces the mortality and morbidity due to CAD and 
CVD.6 
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3.2.3. Statins available: 
Statins currently available for the treatment of hyperlipidemia are6-8 
 Lovastatin 
 Simvastatin 
 Pravastatin 
 Atorvastatin 
 Rosuvastatin 
 Pitavastatin  
 Fluvastatin  
3.2.4. Structure of statins:6 
The different types of statins available vary among themselves in 
their pharmacokinetics, depending upon the chemical structure of individual 
compounds. The only common feature that all statins share is the side group 
which is similar to HMG-CoA. 
3.2.4.1. HMG-CoA: 
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3.2.4.2. Mevastatin: 
   Mevastatin has a hexahydronaphthalene ring. 
 
 
 
 
 
 
3.2.4.3. Lovastatin: 
Lovastatin has a hexahydronaphthalene ring, methyl group 
at carbon 3 and methyl butyrate ester. 
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3.2.4.4. Simvastatin: 
Simvastatin has a hexahydronaphthalene ring and dimethyl 
butyrate ester in its structure. 
 
 
 
 
 
 
3.2.4.5. Pravastatin: 
Pravastatin has a hexahydronaphthalene ring and a methyl 
butyrate ester in its structure. 
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3.2.4.6. Fluvastatin: 
The structure of fluvastatin has a heptanoic acid side chain 
 
 
 
 
 
 
 
3.2.4.7. Atorvastatin: 
 Atorvastatin has a similar structure of fluvastatin and have a 
heptanoic acid side chain.  
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3.2.4.8. Rosuvastatin: 
Rosvastatin also has similar structure to that of Fluvastatin 
and atorvastatin with a heptanoic acid side chain. 
 
 
 
 
3.2.4.9. Pitavastatin: 
Pitavastatin also has a similar structure to that of rosuvastatin 
with a heptanoic side chain in its structure. 
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3.2.5. Mechanism of action: 
 The role of statin is mainly to reduce the low density lipoprotein levels. 
Statins reduce the levels by preventing the formation of mevalonate. They 
competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
enzyme, reducing the synthesis of mevalonate from 3-hydroxy-3-methylglutaryl-
coenzyme A and is the rate limiting step in the biosynthesis of cholesterol.6 
Normally 70-75 percentage of plasma low density lipoprotein is removed 
by receptor mediated endocytosis by the hepatocytes. In the liver, cholesterol 
esters from low density lipoprotein molecules are hydrolyzed to form free 
cholesterol. When statins are given the de novo synthesis is inhibited. This leads 
to up-regulation of low density lipoprotein receptors on the liver cells and helps 
in the clearance of cholesterol rich plasma low density lipoproteins. This is dose 
dependent and full effect is seen within 6 weeks.39 
Statins in their therapeutic dose can reduce the total cholesterol, 
triglyceride and low density lipoproteins synthesis by 20-50 %, 10-30 % and 30-
55 % respectively and increase the high density lipoprotein levels by 5-15 %.7 
Higher doses of most efficacious statins like atorvastatin, rosuvastatin and 
simvastatin can reduce the triglyceride levels by 25-35 %.7 
The mechanism of action of statin is schematically presented in Figure 3. 
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Figure 3. Mechanism of action of statins 
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3.2.6. Pharmacological action: 
Statins reduce levels of low density lipoprotein, very low density 
lipoprotein and total cholesterol. Added to this, other effects which are beneficial 
like stabilization of plaque on the vessel wall, inhibition of thrombus formation, 
reduction in the viscosity of serum, anti-inflammatory and antioxidant effect are 
also seen.40 These beneficial effects are due to the inhibition of vasoconstriction, 
activation of re-endothelialization and upregulation of endothelial nitric oxide 
synthase.41  
Anti inflammatory and antioxidant effects are also seen due to the 
regulation of the inflammatory mediators.41   
 3.2.6.1. Antiatherogenic effects of statins:42 
  Nuclear factor kappa B plays a vital role in the initiation of 
inflammatory process leading to atherosclerosis, this activity was reduced 
by the inhibition of synthesis of farnesylated proteins by statins. They also 
inhibit the proliferation and migration of smooth muscle cells from vessel 
media into the intima and also the conversion of contractile cells to 
reparatory type which prevents the atherosclerotic plaque. 
 3.2.6.2. Effect of statins on endothelial dysfunction:42 
Statins increase the endothelial blood flow and nitric oxide 
synthesis thereby improving the endothelial function. 
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3.2.6.3. Anti-inflammatory effects of statins:42 
Various studies have proven that inflammation is greatly associated 
with CAD and atherosclerosis is dominated by immune cells. The 
elevation in the inflammatory markers like C- Reactive Protein [CRP], 
interleukin-6 [IL-6], inter cellular adhesion molecule-1 [ICAM-1] and 
serum amyloid A are associated with the high risk leading to initial and 
recurrent cardiovascular events.  
Increase in the CRP levels is related to increased migration of 
monocyte and increased LDL uptake by macrophages. Studies have 
proven that there was a decrease in the levels of CRP which was greater 
with atorvastatin and rosuvastatin. 
 3.2.6.4. Antiproliferative effects of statins:42 
Statins decrease the plaque growth by reducing the synthesis of 
extracellular matrix, proteins like Rac 1 and Rho A. They also inhibit the 
conversion of reparatory-type cells from contractile smooth muscle cells 
and also inhibit the migration of reparatory-type cells into the intima from 
the arterial media. 
3.2.6.5. Effect of statin on angiogenesis:42 
The endothelial proteinkinase Akt is activated which in turn 
stimulate the endothelial nitric oxide synthetase in the endothelium and 
neoangiogenesis. Thus stimulated protein kinase Akt improves the 
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metabolism of myocardial oxygen and also increases the angiopoetine 
level. 
3.2.6.6. Effect of statin in stabilizing the plaque rupture:42 
They decrease the activity of MMP1 and MMP3, a 
metalloproteinases which play the vital role in rupture of the plaque. They 
also reduce the arterial stiffness and rheology thereby reducing the blood 
pressure on long term use. 
3.2.6.7. Effect of statins on thrombus formation:42 
Statins inhibit the generation of thrombin by decreasing the activity 
of plasminogen activator inhibitor-1 [PAI-1], also decrease the blood 
fibrinolytic activity. 
3.2.6.8. Effect of statins on stabilization of plaque:42 
Even though various effects have been described for the 
atherosclerotic plaque stability, the important effect is due to reduction in 
the size of the lipid core of the plaque and prevention of the inflammatory 
reaction.  
 3.2.6.9. Effect of statin as an antioxidant:43  
Alanazi in his study have shown that treatment with pravastatin in 
subjects taking primaquine can prevent oxidative damage by their 
antioxidant activity. It was also concluded that pravastatin can help in 
restoring the functions of the erythrocyte by reducing the oxidative stress. 
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3.2.6.10. Other findings on effects of statins: 
Zhou et al.44 conducted a meta-analysis in patients with acute 
coronary syndrome, and found that those who had taken statin therapy had 
reduced risk of atrial fibrillation. 
Novaro et al.45 in their retrospective analysis of 174 patients who 
were suffering from mild to moderate calcific aortic stenosis showed that 
there was a significant reduction in the progression of the disease. 
Another randomized control trial conducted on patients planned for 
coronary intervention pretreated with atorvastatin 40 mg per day for one 
week by Pasceri et al.46 This study showed that there was a significant 
reduction in the cardiac markers for myocardial damage like CK-MB, 
troponin I and myoglobulin. 
Vyas et al.47 who conducted a multicenteric randomized study to 
prove the anti arrhythmic effects of statins in patients suffering from 
ventricular tachycardia [VT] or ventricular fibrillation [VF] with 
automatic implantable cardioverter-defibrillator, suggested that statins 
were associated with reduction in the episodes of VT or VF. 
Kuwana et al.48 conducted a prospective, open-label, single center 
pilot study in patients with systemic sclerosis and concluded that statins at 
a dose of 10 mg per day for a period of 24 months might be helpful in 
treating the vascular complications of systemic sclerosis. 
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A retrospective cohort study conducted by Lokhandwale et al49 on 
asthmatic patients who were on inhaled corticosteroids showed that statins 
had beneficial effects in preventing the acute exacerbation of asthma. 
Multicenteric retrospective analysis of 5011 patients suffering from 
heart failure by evaluating the inflammatory cytokines and high-
sensitivity C-reactive protein [hs-CRP] by McMurray et al.50 had shown 
that there was a better outcome with rosuvastatin in patients having       
hs-CRP ≥2.0mg/L. 
Everett et al.51 conducted a randomized, double blinded, placebo 
controlled, multicenteric trial with rosuvastatin involving 17802 patients 
from 26 countries at 1315 sites. This study showed that there was a 
reduction in the incidence of stroke by 48 % and the risk of hemorrhagic 
stroke was not increased. 
Han et al.52 conducted a prospective, multicenteric, controlled 
clinical trial in China which randomized 2998 type 2 DM patients with 
chronic kidney disease who were planned to undergo coronary or 
peripheral arterial angiography, rosuvastatin 10 mg/day  was administered 
2 days before and 3 days after the procedure. The study outcome showed 
that acute kidney injury due to contrast was significantly low in 
rosuvastatin group and during the follow-up after 30 days showed that 
worsening of heart failure was also significantly reduced. 
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Ghosh et al.53 conducted a study on mice and proved that 
pravastatin have a protective effect on the dopaminergic neurons in         
1-methyl-4-phenyl-1,2,3,6-tetra hydropyridine [MPTP] induced 
parkinsonism. 
Hsu et al.54 in their retrospective cohort study which included 1738 
blood stream infection [BSI] patients in United States of America 
revealed that statin use within 1 month period before BSI reduced the 
mortality. 
Kwong et al.55 in their cohort study stated that there was a 
statistically significant protection against morbidity and mortality in 
elderly patients with influenza. 
Lee et al.56 conducted a 1 year retrospective study on 791 patients 
with benign prostatic hyperplasia [BPH] and proved that statins had 
reduced the prostate volume and prostate specific antigen. 
A nested case-control study conducted by McGwin et al.57 at the 
Veterans Affairs Medical Centre in Birmingham on patients newly 
diagnosed to have age related maculopathy [ARM] revealed that ARM 
was significantly less with patients who had treatment with statin. 
Harbi et al.58 in their nested cohort study of 2 randomized 
controlled trials including 763 patients who were critically ill proved that 
statin therapy have reduced hospital mortality. 
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Wan et al.59 did a meta-analysis of 5 randomized clinical trial 
[RCT] and 27 observational studies including 3,37,648 patients. The study 
revealed that RCT did not show significant reduction in the in-hospital 
mortality, whereas there was a significant decrease in the in-hospital 
mortality in the observational study. 
Sathyapalan et al.60 conducted a randomized, double blinded, 
placebo controlled trial with atorvastatin in patients suffering from 
polycystic ovary syndrome and showed that there was a significant 
reduction in the total cholesterol [TCH], triglycerides [TGL], free 
androgen index, total testosterone, serum insulin levels and homeostatic 
model assessment-insulin resistance [HOMA-IR]. 
Al-Ghoul et al.61 conducted a study on male mice by administering 
simvastatin and melatonin following major thermal injury and proved that 
simvastatin had anti-inflammatory action. 
Moraes et al.62 conducted a study on mice with fluvastatin and 
simvastatin and proved that fluvastatin had a better inhibition of 
aggregation of platelet when compared to simvastatin. 
So altogether statins have proved their effectiveness to improve 
coronary artery disease and cerebrovascular disease. 
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3.2.7. Pharmacokinetics: 
3.2.7.1. Absorption: 
Statins are well absorbed orally and are their absorption is 
enhanced by food.63 The intestinal absorption varies between 30-85 %6 
except for fluvastatin which is absorbed almost completely.38 
3.2.7.2. Distribution: 
Pravastatin is bound 50 percent to the plasma where as all other 
statins are bound 95 percentage or more  are only 50 % bound.6 
3.2.7.3. Metabolism: 
All statins undergo extensive first pass metabolism which is 
primarily mediated by organic anion-transporting polypeptide 1 B1 
[OATP1B1], an organic anion transporter.6 Except rosuvastatin, all other 
statins are metabolized by CYP3A4.7 
3.2.7.4. Excretion: 
After biotransformation in the liver, all statins and 70 % of its 
metabolites get eliminated through the faeces6 and 5-20 % gets excreted in 
the urine.38 
3.2.8. Uses: 
 Statins are first line drugs useful in the treatment of both primary as well 
as secondary hyperlipidemia associated with diabetes mellitus.7,63 Statins can 
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reduce morbidity and mortality due to coronary artery disease and hence used to 
treat patients with myocardial infarction, angina, stroke and transient ischemic 
attack.63 
3.2.9. Adverse drug reaction: 
Even though statins are well tolerated, they can also cause adverse effects 
like headache, muscle pain, gastrointestinal disturbances, increased liver 
enzymes, insomnia and rash.7,8 Other serious and rare adverse effects include 
rhabdomyolysis and angio-oedema.8 Adverse effects like acute pancreatitis9-14 
and decreased libido had been reported.64 
The effect of statin on the muscle is due to the elevated respiratory 
exchange ratio in asymptomatic persons, whereas in symptomatic patients there 
is an off-statin respiratory exchange ratio. This alteration in the respiratory 
function of the cell contributes to the myopathy in patients on statin therapy.65 
Rhabdomyolysis is one of the dangerous and well recognized adverse 
drug reaction due to statin therapy which occurs due to severe muscle damage 
causing rise in the creatinine kinase levels upto 10 times the normal upper limit. 
This is usually associated with renal dysfunction which further leads to renal 
failure and even death.65 
3.2.10. Drug interaction: 
Statins are metabolized by cytochrome P [CYP] 450 isoenzymes. The 
isoenzyme CYP3A4 is responsible for the metabolism of atorvastatin, lovastatin 
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and simvastatin and CYP2C9 is responsible for the metabolism of fluvastatin and 
rosuvastatin.66 
The inducers of CYP3A4 include phenytoin, phenobarbital, barbiturates, 
rifampin, dexamethasone, cyclophosphamide, carbamazepine, troglitazone and 
omeprazole; whereas they are inhibited by ketoconazole, itraconazole, 
fluconazole, erythromycin, clarithromycin, tricyclic antidepressants, nefazodone, 
venlafaxine, fluvoxamine, fluoxetine, sertraline, cyclosporine A, tacrolimus, 
mibefradil, diltiazem, verapamil, protease inhibitors, midazolam, corticosteroids, 
grapefruit juice, tamoxifen and amiodarone.66 
The inducers of CYP2C9 includes rifampin, Phenobarbital, phenytoin and 
troglitazone and inhibitors include ketoconazole, fluconazole and 
sulfaphenazole.66 
These inhibitors can increase the blood statin levels leading to toxicity 
and inducers can decrease the levels of blood statin causing therapeutic failure.7 
3.2.11. Contraindication: 
Even though there are no evidence to say that statins are contraindicated 
in pregnancy and lactation, they are avoided in this condition as they are not 
proved to be safe.63 
Drugs which act through the CYP3A4 and CYP2C9 are also 
contraindicated with statin therapy as statins also act through these hepatic 
isoenzymes which can either get induced or inhibited by this drugs.66 
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3.2.12. Pharmacogenetics: 
Lagos et al.67 conducted a study on population of Amerindian Chile to 
evaluate the response of atorvastatin in patient with apolipoprotein E [APOE] 
polymorphisms in their variants of rs429358 and rs7412 and the low-density 
lipoprotein receptor [LDLR] gene 1959C>T single nucleotide polymorphism 
[SNP] of variant rs5925. This study proved that the genotype E3/4 carriers had a 
less reduction of LDL when compared to E3/3 genotype. 
Santos et al.68 included 156 heterozygous familial hypercholesterolemia 
patients caused due to low-density lipoprotein receptor gene mutation from 
Brazil in their study and the result showed that there is a significant difference 
in the reduction of the low-density lipoprotein level below with the genotype 
AA when compared with GG and GA phenotype. 
3.3. Serum Lipase: 
3.3.1. Introduction: 
  Lipase [LPS], is an enzyme that produces alcohols and fatty acids 
by hydrolyzing the linkage of fat esters.69 It is a single-chain glycoprotein 
having a molecular weight of 48,000 Dalton [Da] and with about 5.8 
isoelectric point.70 Even though there are three iosenzymes of lipase, L2 is 
considered to be clinically significant as they are more specific and 
sensitive.69 
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3.3.2. Synthesis: 
  Lipase is mainly synthesized from the pancreas and also from the 
stomach, pulmonary mucosa and intestine.69,70 Most of the lipase in the 
serum which are active are derived from the pancreas.70 
3.3.3. Properties of Lipase: 
  Lipase present in the serum are stable at room temperature for a 
period of 1 week with negligible loss of activity or stable for 3 weeks at 4 ̊ C 
provided hemolysis has not occurred as hemoglobin inhibits the serum lipase 
activity.69 Serum sample can also be stored in frozen state for several years 
without change in the activity of the lipase.70 
3.3.4. Action of Lipase: 
  Lipase helps in formation of 2-monoglyceride intermediate and 
long-chain fatty acids by catalyzing the hydrolysis of dietary triglycerides 
partially.69 Pancreatic lipase specifically acts on the 1 and 3 positions of the 
triglyceride molecule and the rate of the reaction is controlled by the protein 
co-enzyme colipase and bile salts.69 
3.3.5. Normal levels: 
  The normal level of lipase is determined to be <38 U/L at 37 °C 
temperature.69 
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3.3.6. Factors affecting normal levels: 
 There are various factors that can influence the levels of lipase in 
the serum. This can lead to either increase in lipase level or decrease in 
lipase level. The various factors are enumerated below. 
3.3.6.1. Hyperlipasemia: 
  The conditions that can lead to increase in serum lipase 
level include penetrating duodenal ulcer, perforation of peptic ulcer, 
intestinal obstruction, acute cholecystitis, acute pancreatitis, pancreatic 
duct calculus causing obstruction, pancreatic cancer, in patients with 
decreased glomerular filtration rate, Endoscopic Retrograde Cholangio 
Pancreatography [ERCP] and opioids.69,70 Serum lipase may also be 
increased in conditions like cystic fibrosis, celiac disease, crohns 
disease.71 
3.3.6.2. Hypolipasemia: 
  Factor that leads to decreased lipase level is destruction / 
damage to the pancreatic tissue which can lead to raised cholesterol 
and triglyceride levels, rise in blood pressure, difficulty in losing 
weight and varicose veins.71 
3.3.7. Estimation of Lipase: 
  There are various methods available for measuring the activity of 
lipase and each follows different principles. The various techniques include 
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titrimetric, turbidimetric, spectrophotometric, fluorometric and immunologic 
techniques which use both the triglyceride and nontriglyceride substrates for 
the determination of lipase.70 
   The estimation of serum lipase done in this study is a recently used 
technique which follows the principle of direct reaction and have more 
specificity for pancreatic lipase.70 Lipase catalyses the hydrolysis of              
1,2-O-dilauryl-racglycero-3-glutaric acid-(4-methyl-resorufin)-ester which 
has two glycerol ether bonds and one ester bond to form 1,2-O-dialuryl-rac-
glycerol + acid-(6’-methylresorufin)-ester. Then in the presence of water 
acid-(6’-methylresorufin)-ester is converted to glutaric acid and 
methylresorufin. The concentration is measured at 580 nm from the rate of 
the red dye formation. 
3.3.8. Clinical Significance: 
  Measurement of serum lipase is useful in the diagnosis of acute 
pancreatitis [AP] as the clinical sensitivity is 94 %71 and the clinical 
specificity is 80 to 100 % obtained from studies on varied population.70 
Serum level of LPS increases within 4-8 hours, reaches the peak by 24 hours 
and declines within a period of 7 to 14 days in case of AP.70 It has been 
reported that the increase of serum lipase by 2 to 5 folds than the upper limit 
is diagnostic of acute pancreatitis and is more specific.71 
  Hence serum lipase estimation is recommended, over estimation of 
serum amylase [AMY] level as a diagnostic tool for acute pancreatitis and it 
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is not necessary to determine the levels of both serum lipase and amylase to 
confirm acute pancreatitis.70 
3.4. Blood Glucose: 
3.4.1. Introduction: 
Glucose is the most essential substance from which energy is 
obtained for the normal functioning of the body tissue and continuous supply 
of energy to the brain cells is dependent on glucose level in the blood.72 
Derangement in the metabolism of glucose can lead to life threatening 
conditions. Blood glucose level ranging between 70 to 110 mg/dl in the 
fasting state is required for the normal functioning of tissues and cells.72 A 
daily allowance of 160 grams [gms] is needed for the body to function 
normally, out of this 120 gms of glucose is required for the human brain to 
function.73 
3.4.2. Sources of glucose:73 
  The main source of glucose is derived from the diet in the form of 
carbohydrates, fructose, galactose and mannose. Glucose is the main source 
of energy which is stored as glycogen and is then converted to glucose 
whenever there is a demand for glucose by the cells. 
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3.4.3. Synthesis:73 
  The glucose is mainly synthesized by three major metabolic 
pathways which includes gluconeogenesis, glycogenolysis and galactose 
metabolism. 
3.4.3.1. Gluconeogenesis:73 
  It is defined as a synthesis of glucose from non-carbohydrate 
aminoacids like lactate and glycerol. 
  Gluconeogenesis mainly occurs in the cytosol and some occurs in 
the mitochondria. The process of gluconeogenesis takes place mainly in 
the liver and in kidney to some extent and is regulated depending upon the 
availability of glucagon and insulin. 
Gluconeogenesis occurs during fasting and meets the basal 
requirement of glucose needed for the body. It also effectively eliminate 
the metabolites like lactate, glycerol and propionate that is produced in the 
tissue and accumulated in the blood.73 
 3.4.3.2. Glycogenolysis:73 
  It is a process of breakdown of glycogen to form glucose and is an 
irreversible reaction. Glycogen, a storage form of glucose is mainly stored 
in the liver [6-8%] and in the muscle [1-2%]. It is stored in the form of 
granules in the cytosol where the enzymes that are helpful in glycogen 
synthesis and breakdown are present. The main function of the glycogen 
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in the liver is to maintain the normal levels of blood glucose, especially 
between the meals. Glycogen gets stored in the liver during the surplus 
feeding period and gets utilized during the fasting state. Apart from this, 
the glycogen in the muscle helps in the formation of adenosine 
triphosphate [ATP] and serves as a fuel during the contraction of the 
muscle. 
  Even though fat is also a source of reserve energy for the body, 
glycogen is considered to be useful for day to day activity as it can be 
easily metabolized even in the absence of oxygen and utilized for the 
continuous supply of glucose. 
 3.4.3.3. Galactose metabolism:73 
  It is a process of formation of glucose from galactose along with 
the synthesis of lactose. 
  3.4.3.3.1. Sources of galactose: 
  The primary source of galactose is milk and milk products 
and is available as a disaccharide lactose in the diet.73 
  3.4.3.3.2. Metabolism:73 
 Galastose is formed in the cells by the degradation of 
glycoprotein and glycolipids. Lactase also known as β-
galactosidase which is present in the intestinal mucosa hydrolyses 
lactose to galactose and then to glucose.   
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3.4.4. Glucose transport mechanism:73 
  For a normal functioning of the living cell, it is necessary that the 
formed glucose has to enter the cell from plasma. The concentration of 
glucose in the plasma is very high when compared to the glucose in the cells. 
The glucose that is present in the plasma cannot enter the cell by diffusion. 
There are two specific transport systems that help the transport of glucose 
from the plasma to the cells. 
a. Insulin-independent transport system 
b. Insulin-dependent transport system 
3.4.4.a. Insulin-independent transport system: 
 This system of glucose transport is a carrier mediated uptake and is 
present in hepatocytes, erythrocytes and brain cells.73 
3.4.4.b. Insulin-dependent transport system: 
 It is a glucose transport system which requires insulin for the 
transport of glucose in to the cells and occurs in the muscle and adipose 
tissue.73 
3.4.5. Transporters of glucose:72 
There are totally six transporters that are identified as transporters 
of glucose which includes GLUT-1, GLUT-2, GLUT-3, GLUT-4, GLUT-5 
and GLUT-7. These transpoters are seen in the cell membrane and have 
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specificity towards each tissue. For example GLUT-1 is seen more in 
erythrocytes and GLUT-4 is seen in skeletal muscle and adipose tissue. 
3.4.6. Regulation of blood glucose: 
 Blood glucose plays a major role in maintaining the normal functioning of 
the cell and there is a need for the plasma concentration of the glucose to be 
maintained within the normal range.72  
The regulatory mechanism of blood glucose is schematically 
represented in Figure 4. 
Figure 4. Diagrammatic representation of maintenance of blood glucose74 
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The blood glucose concentration is maintained in the normal range 
by various hormones that regulates the movement of glucose in and out of 
the circulation.74 Insulin is the hormone that decreases the blood glucose 
level where as glucagon, epinephrine, cortisol and growth hormone, the 
counter-regulatory hormones increase the concentration of blood glucose.74 
Maintenance of blood glucose is diagrammatically represented in Figure 4.  
3.4.7. Normal levels of blood glucose:75 
  Maintenance of blood glucose within the normal range is needed 
for the normal functioning of cells.  
  The normal levels of blood glucose and glycosylated hemoglobin 
[HbA1C] levels is shown in table 2. 
Table 2. Normal blood glucose and glycosylated hemoglobin [HbA1C] levels75 
 
 
Normal Pre diabetes Diabetes Mellitus 
Fasting Plasma 
Glucose 
< 100mg/dl 100-125mg/dl > 126mg/dl 
Post Prandial 
Plasma Glucose 
< 140mg/dl 140-199mg/dl > 200mg/dl 
HbA1C < 5.6% 5.7-6.4% ≥ 6.5% 
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3.4.8. Factors affecting normal levels: 
3.4.8.1. Hyperglycemia: 
 Diabetes mellitus [DM] is a metabolic disorder that present with 
hyperglycemia which is caused due to the reduction in the insulin 
secretion, glucose utilization and increased production of glucose.75 
 Kim et al.76 in their study conducted on the disturbances of 
hormone and metabolism due to altered sleep has shown that 
disturbances or deprivation of sleep has higher association of 
developing obesity, diabetes, insulin resistance and changes in the  
regulation of leptin and ghrelin. 
 Ulhoa et al.77 have proved the association between metabolic 
syndrome and the work of people in day/night shift. It was also stated 
that the glycemic control among shift workers is poor when compared 
to non-shift workers and the risk associated with the development of 
type 2 DM also increases by two fold. 
3.4.8.1.1. Causes of hyperglycemia: 
The various causes of hyperglycemia includes type 1 DM, type 2 
DM, maturity onset diabetes of the young, gestational DM, genetic 
defects, disease of the exocrine pancreas and Endocrinopathies, drugs, 
infections and genetic variations.75  
The various causes of hyperglycemia is mentioned in table 3. 
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 Table 3. Various causes of hyperglycemia75 
 
Causes of hyperglycemia 
Type 1 DM  
Type 2 DM  
Gestational diabetes mellitus [GDM] 
Maturity onset diabetes of the young [MODY] 
Drugs  
 Glucocorticoids 
 Nicotinic acid 
 β-adrenergic agonists 
 Diuretics [Thiazides] 
 Adrenaline  
 Diazoxide 
 Antipsychotics  
 mTOR inhibitors 
 Hydantoins 
 Asparginase 
 α-interferon 
 Protease inhibitors 
 Calcineurin 
 Vacor (rodenticide) 
Infections  
 Coxsaxkievirus  
 Cytomegalovirus 
 Congenital rubella 
 
Diseases of the exocrine pancreas  
 Pancreatitis 
 Cystic fibrosis 
 Fibrocalculous pancreatopathy  
 Hemochromatosis 
 Neoplasia 
 Mutations in carboxy ester lipase 
 Surgical removal of Pancreas 
Endocrinopathies   
 Hyperthyroidism 
 Cushings syndrome 
 Acromegaly 
 Glucagonoma 
 Pheochromocytoma 
 Aldosteronoma  
 Somatostatinoma 
Genetic syndromes   
 Down’s syndrome 
 Porphyria  
 Turner’s syndrome 
 Huntington’s chorea 
 Myotonic dystrophy 
 Klinefelter’s syndrome 
Immune-mediated diabetes  
 Anti-insulin receptor antibodies  
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3.4.8.1.2. Complications of hyperglycemia:78 
Hyperglycemia can lead to acute complications like diabetic 
ketoacidosis and heperglycemic hyperosmolar state. Chronic 
hyperglycemia can lead to microvascular complications that includes 
retinopathy, nephropathy and neuropathy and macrovascular 
complications like coronary artery disease [CAD], peripheral vascular 
disease [PVD] and cerebrovascular disease [CVD]. 
 Non vascular complications that can occur due to hyperglycemia 
includes infections, gastroparesis, diarrhea, uropathy, sexual 
dysfunction, hearing loss, cataract, glaucoma, periodontal disease, skin 
changes and cheiroarthropathy. 
3.4.8.2. Hypoglycemia: 
Hypoglycemia is a condition in which there will be a reduction 
in the blood glucose level below 70mg/dl which can lead to morbidity 
and in some cases it can be fatal.79  
 3.4.8.2.1. Types of hypoglycemia:80 
  Hypoglycemia is classified in to 4 types namely 
a) Insulin-induced hypoglycemia 
b) Postprandial hypoglycemia [Reactive hypoglycemia] 
c) Fasting hypoglycemia 
d) Alcohol-related hypoglycemia 
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3.4.8.2.1.a. Insulin-induced hypoglycemia:80 
Diabetic patients who are treated with insulin for achievement of 
tight glycemic control are frequently affected. These patients, when 
conscious are managed by oral carbohydrate and unconscious patients are 
treated with subcutaneous or intramuscular glucagon or intravenous 
glucose. 
3.4.8.2.1.b. Postprandial hypoglycemia:80 
 This is a common form of hypoglycemia caused due to excessive 
release of insulin followed by meal and usually the plasma glucose levels 
comes back to normal without any management. This can be avoided by 
having light meals frequently than having large three meals. 
3.4.8.2.1.c. Fasting hypoglycemia:80 
 Fasting hypoglycemia occurs due to the decrease in the hepatic 
glycogenolysis or gluconeogenesis and is commonly seen in 
hepatocellular damage, adrenal insufficiency and in persons who have 
taken large volume of ethanol. 
3.4.8.2.1.d. Alcohol related hypoglycemia:80 
 It mainly occurs due to ethanol mediated increase in Nicotinamide 
dinucleotide hydride [NADH] causing decreased synthesis of glucose by 
directing the intermediates like pyruvate and oxaloacetate in to the 
alternate pathways.  
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3.4.8.2.2. Causes of hypoglycemia:81 
   The various causes of hypoglycemia are classified depending upon 
the various age groups. The commonest causes of hypoglycemia in neonates 
includes small for gestational age or prematurity, toxemia of pregnancy, 
maternal diabetes mellitus, respiratory distress syndrome, cold stress and 
polycythemia. Various causes of hypoglycemia in infants includes ketotic 
hypoglycemia, congenital enzyme defects, glycogen storage disease, 
deficiency of gluconeogenic enzymes, galactosemia, hereditary fructose 
intolerance, leucine hypersensitivity, endogenous hyperinsulinism, Reye’s 
syndrome and idiopathic causes. The various causes of hypoglycemia in 
adult who are under treatment with drugs, include insulin or insulin 
secretagogue, quinine, indomethacin, etc. Critical illness like hepatic, renal 
or cardiac failure, inanition, deficiency of glucagon, epinephrine and 
cortisol, sepsis and malaria can cause hypoglycemia. In adult who appears to 
be apparently normal, hypoglycemia can be due to endogenous 
hyperinsulinism, insulinoma, functional β-cell disorders and antibody to 
insulin secreted or to insulin receptors. Apart from these, hypoglycemia can 
be due to post gastric bypass, insulin secretagogues, insulin autoimmune 
disorder and non-insulinomal pancreatogenous etiology. 
3.4.9. Estimation of blood glucose: 
Estimation of glucose can be done by using serum plasma or whole 
blood. Nowadays, most of the laboratories use serum or plasma for 
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estimation of glucose.81,82 The concentration of glucose in the plasma is 11% 
higher when compared to the concentration of glucose in the whole blood.82 
The blood glucose can be estimated in the state of fasting for 8 to 10 
hours, post prandial blood glucose after 2 hours of food and random blood 
glucose at any time of the day.82  
 Glucose estimation is most commonly done using hexokinase and 
glucose oxidase peroxidase methods. Other investigations for measurement 
of blood glucose includes modified glucose oxidase method and glucose 
dehydrogenase method.81,82 
3.4.10. Stability of blood glucose: 
  The glucose level in the serum obtained from centrifuged clotted 
blood is decreased by 5 to 7 % in 1 hour at room temperature due to 
glycolysis. So fluoride is always added to the blood collected for estimation 
of glucose.81  
3.4.11. Clinical Significance:74 
  The importance of monitoring the blood glucose levels in clinical 
practice was to diagnose and treat DM and its complications like diabetic 
keto acidosis [DKA], hyper osmolar non ketotic coma [HONK] and 
hypoglycemia. It also helps in monitoring the treatment of DM to restore the 
euglycemic state and to correct other metabolic disturbances associated with 
DM.  
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Estimation of blood glucose levels helps in knowing the present 
glycemic status in diabetic patients. 
3.5. Pancreatitis: 
3.5.1. Introduction: 
Pancreas, a soft lobulated gland is located in the posterior abdominal wall 
behind the stomach consisting of two parts exocrine and endocrine and have less 
of connective tissue.83 Pancreas is composed of the acini that secretes digestive 
juices and the islets of Langerhans that secrete insulin and glucagon.84  
Pancreas is comprised of four major cells alpha [α] cells, beta [β] cells, 
delta [δ] cells and PP cells and two minor cells D1 cells and enterochromaffin 
cells.83 
Alpha cells form 20 % of the total cells and are dense round granular cells 
which are responsible for the secretion of glucagon and have a diabetogenic 
property.83 Beta cells are the cells that secrete insulin and have an anti-
diabetogenic function.83 They comprise of 68 % of the major cells.83 Delta cells 
form 10% of the major cells and are responsible for the secretion of somatostatin 
that inhibits the release of insulin and glucagon.83 
PP cells contribute to 2 % of the major cells, and are small and dark 
granules that secrete the hormone pancreatic polypeptide. This helps in the 
stimulation of gastrointestinal enzymes and inhibition of intestinal motility.83 
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D1 cells are responsible for the secretion of vasoactive intestinal 
polypeptide [VIP] which helps in inducing glycogenolysis and hyperglycemia. 
Vasoactive intestinal polypeptide also stimulates the secretion of gastrointestinal 
fluid which can lead to secretory diarrhoea.83  
 3.5.1.1. Physiology of pancreas:84 
  Pancreas is responsible for the secretion of two major hormones 
insulin and glucagon which are essential for the normal metabolism of 
glucose, lipid and protein. Apart from these hormones they also secrete 
digestive enzymes and other hormones like amylin, somatostatin, and 
pancreatic polypeptide. 
3.5.2. Definition: 
  Acute pancreatitis is an acute inflammatory disorder of the 
pancreatic acinar cells85,86 and usually presents with abdominal pain and 
elevation in the serum amylase and lipase levels.85 
3.5.3. Prevalence: 
  The prevalence of AP ranges between 13 – 45 / 100000 person in a 
year and a population study revealed that there was a large increase in the 
AP incidence.87 
  The incidence of AP has grown up to 10 times during the past 20 
years and the mortality due to AP ranges between 2 to 9 % and it depends 
upon the severity of the disease.88 
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3.5.4. Causes: 
  The various major causes that can lead to AP includes gall stones 
[30-60 %], alcohol [15-30 %], ERCP [5-20 %], hypertriglyceridemia [1.3-
8.3 %] and drugs like azathioprine, 6-mercaptopurine, sulfonamides, 
tetracycline, anti HIV-drugs, estrogens, valproic acid and 5-aminosalycylic 
acid [2-5 %].89  
The mechanism behind the drug induced AP is either by 
hypersensitivity reaction or due to the toxic metabolite generation.90 
Some of the other causes of AP includes blunt trauma to the 
abdomen and abdominal and non abdominal surgeries. The uncommon 
causes of AP includes vasculitis, connective tissue disorders, 
thrombocytopenic purpura [TTP], hypercalcemia, periampullary 
diverticulum, pancreas divisium, cancer of the pancreas, hereditary 
pancreatitis, cystic fibrosis of pancreas, renal failure, viral infections, 
parasitic infection and type1 and 2 auto immune disorder.89 
  Apart from the above mentioned drugs that can cause AP, there are 
case reports on statin induced AP. 
  Anagnostopoulos et al.9 reported a case of AP in a 56 year old 
patient from Greece who was treated with pravastatin 20mg for a period of 6 
months where other causes of AP were ruled out. The patient again reported 
with AP after 5 months duration which recurred after 3 days of initiating 
pravastatin self medication. 
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  Chintanaboina et al.10 reported a 67 year old female on rosuvastatin 
and clonidine who presented with abdominal pain and vomiting for 7 days 
and investigation confirmed AP. The patient was treated with conservative 
management and medications were stopped during the stay in the hospital. 
The patient responded and was discharged with an advice to continue her 
routine medications but she again presented with AP after 2 months. After 
thorough workup the possible cause of AP was suspected to be rosuvastatin 
and the drug was withdrawn and she was completely asymptomatic during 
the 18 months follow-up. 
  Singh et al.11 reported about a case of AP in a 77 year old female 
who was on rosuvastatin which subsided on stopping the drug. Detailed 
treatment history revealed that she suffered a similar episode a year back 
which was precipitated by atorvastatin.  
Antonopoulos et al.12 reported about a 58 year old Caucasian male 
on treatment with acetyl-salicylate for 6 years and simvastatin for the past 2 
months who presented with epigastric pain and vomiting and investigations 
revealed AP. 
Tsigrelis et al.13 in their case report stated about a 50 year old 
female who developed AP following 3 days of treatment with pravastatin 
where all the other possible causes of AP were ruled out. 
Etienne et al.14 reported a case of a 58 year old male patient who 
presented with abdominal pain and vomiting who was under valproic acid, 
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omeprazole and simvastatin. Investigation revealed that serum amylase and 
lipase to be elevated which was suggestive of AP. Simvastatin was suspected 
to be the cause of AP and was stopped, which resolved the symptoms and 
his lipase dropped to the normal level. 
Suwansiripat et al.91 reported about an 84 year old Thai man who 
was a known case of hypertension, CAD and benign prostatic hypertrophy. 
He was under treatment with simvastatin, aspirin, amlodipine, trimetazidine 
hydrochloride and afluzosin. He was admitted in the hospital with acute pain 
over the epigastric region which was radiating to the middle of back. The 
pain started after taking the dinner and investigation carried out revealed that 
pancreatic amylase and liver function test were higher. Multi detector 
computerized tomography [MDCT] findings were suggestive of acute non-
necrotizing pancreatitis. 
Prajapati et al.92 in their case report mentioned about a 58 year old 
hyperlipidemic male who was on atorvastatin. The patient developed acute 
abdominal pain and vomiting. Clinical examination of the abdomen revealed 
epigastric tenderness and investigations showed elevated lipase levels and 
CT was suggestive of acute pancreatitis. The patient recovered following 
conservative management and after withholding atorvastatin. The causality 
assessment of ADR was probable according to Naranjo and WHO-UMC 
scale. 
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3.5.5. Clinical Features: 
 3.5.5.1. Symptoms:93,94 
  Patients who have an episode of AP usually presents with severe 
abdominal pain usually confined to the epigastric region, but can also 
present all around the abdomen or lower chest. The pain is “knifing” or 
“boring through” in nature which radiates to the back and the pain may be 
relieved by leaning forward. 
The patient will have vomiting and retching even after the stomach 
is empty, but there will be no relief for the pain.  
Fever is another symptom associated with AP. 
3.5.5.2. Signs:93 
The signs that can be elicited on examination of the patients 
include tachycardia, tachypnea, hypotension, hyperthermia, distended 
abdomen due to intraperitoneal fluid, voluntary and involuntary guarding 
of the abdomen, reduced or absent bowel sounds, and left sided pleural 
effusion. 
3.5.6. Investigations: 
3.5.6.1. Laboratory investigations: 
Laboratory investigations that are helpful in the diagnosis of AP 
include serum amylase, serum lipase, phospholipase A2 [PLA2], 
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trypsin/trypsinogen, carboxylester lipase, carboxypeptidase A, colipase, 
elastase, ribonuclease, pancreatitis associated protein [PAP], 
methemalbumin, white blood cell [WBC] count, blood glucose level, 
serum glucagon levels, serum aspartate transaminase [AST], alanine 
aminotransferase [ALT], alkaline phosphatase, bilirubin, serum 
triglyceride level, C-reactive protein, interleukin-6 [IL-6], 
polymorphonuclear leukocyte elastase, urinary trypsinogen activation 
peptide and procalcitonin.95  
Apart for these investigations complete blood count, blood urea 
nitrogen [BUN], serum calcium levels, arterial blood gas [ABG] analysis 
and urinalysis are carried out.96 
Serum amylase and lipase are considered to be the markers that is 
used to diagnose AP97 and they tend to increase by 3 fold than that of the 
normal value.95 Serum lipase is more specific for AP when compared to 
serum amylase, as serum amylase is found to be increased in other 
conditions like salivary gland dysfunction, tumors of salivary gland, 
macroamylasemia, gynaecological diseases, intestinal perforation, 
intestinal infarction, chronic alcoholism, post operative state and renal 
failure.95,98  
There will be an increase in the WBC count, blood glucose level, 
serum glucagon, AST, ALT, alkaline phosphatase, serum bilirubin levels 
and serum triglycerides.95,97 
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PAP is a heat shock protein which is not seen in persons with 
normal pancreatic function, whereas it is remarkably raised in AP and the 
accuracy of identifying the PAP is similar to that of serum amylase.95 
3.5.6.2. Radiological investigations: 
3.5.6.2.1. Radiography:95 
 Plain X-ray of the abdomen suggests both the etiology and 
severity of acute pancreatitis. It is helpful in diagnosing the 
conditions like gall stones, pancreatic stones, pancreatic 
calcification, ascitis and gas in the retroperitoneum. 
 X-ray of the chest in patients with acute pancreatitis shows 
pleural effusion, pulmonary infiltrates, elevated hemidiaphragm, 
basal or plate-like atelectasis which was due to reduction in the 
respiratory excursion. The abnormality in the roentgenogram of 
chest is seen in about 30% patients with acute pancreatitis. 
3.5.6.2.2. Ultrasonography [USG] of abdomen:95 
 It is useful during the initial 24 hours of onset of symptoms 
in identifying the gall stones, dilation of bile duct, ascites and 
diagnosing the abnormalities in the pancreas. 
 The pancreas may be enlarged and hypoechoic. 
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3.5.6.2.3. Computerized Tomography [CT]:95 
 CT is considered to be the important radiological test in 
diagnosing AP and its complications related to abdomen. The three 
major indications to proceed for a CT is to exclude other 
abdominal conditions, staging the severity of AP and to identify 
the other abdominal complications of AP. 
3.5.6.2.3.1. Grading system:95 
 There are two main systems which help in grading 
the severity of the disease by CT i.e. grading system of 
Balthazar and CT severity index [CTSI]. 
3.5.6.2.4. Magnetic Resonance Imaging [MRI]:95 
 MRI is also helpful in obtaining the details about the 
severity of AP as CT does. MRI is helpful in identifying the 
necrosis of the pancreas and fluid collections in the abdomen. It is 
much better than CT and is equally good as ERCP and endoscopic 
USG. 
3.5.7. Predictors of severity:95 
  CT and MRI plays a major role in predicting and grading the 
severity of pancreatitis and is useful in the early stage of the disease in order 
to prevent the complications and to improve therapy. 
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There are various scoring systems which helps in grading the 
severity of pancreatitis which includes Ranson’s score, acute physiology and 
chronic health evaluation II [APACHE II] scores, bedside index of severity 
in acute pancreatitis [BISAP], blood urea nitrogen [BUN], organ failure and 
peritoneal lavage to rule out infection. 
3.5.8. Treatment: 
  The main role of treatment in AP is the alleviation of pain, 
correction of fluid volume and metabolic abnormalities, inhibition of 
enzymes, secretions and inflammation and supplementation of nutrition.99,100 
 3.5.8.1. Management of pain: 
  The most important sign of AP is the pain and the management of 
pain should be the foremost aim clinically. Non steroidal anti-
inflammatory drugs [NSAIDs] are useful in the management of mild pain, 
where as weak opioids are helpful in patients having moderate to severe 
pain and in patients where NSAIDs did not relieve the pain. Patient who 
did not respond to weak opioids can be put on strong opioids.99 
Metamizole, an NSAID of choice given at a dose of 2 gram/8hour 
[h] intravenously [IV], Buprenorphine, an opioid of choice given at a dose 
of 0.3 g/4 h IV are the first choice of analgesics.99 Meperidine was 
traditionally used as it does not alter the function of spincter of Oddi 
significantly and will not cause pancreatitis.100 
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3.5.8.2. Fluid management: 
Resuscitation with fluid plays a vital role in the management AP 
during the early stage and helps in improving the clinical outcome.99 
Intravenous fluid and electrolytes replacement plays a major role and 
dextran helps in expanding the intravascular volume and improves the 
blood flow to the pancreas.100 
The main goal is to maintain the blood volume in the circulation in 
order to maintain the heart rate, blood pressure, central venous pressure 
and renal function by maintaining the urine output of >0.5 ml/h/kilogram 
[kg] body weight which is essential in Management.99 
Zhao et al.101 conducted a randomized controlled trial involving 
120 patients with severe acute pancreatitis [SAP] who were randomized in 
to three groups namely normal saline [NS] [NS group], NS and 
hydroxyethyl starch [HES] [SH group] and NS, HES and glutamine [SHG 
group] and resuscitation was done. The author finally concluded that the 
combination of SHG in management was found to be most efficient 
among these in reducing the inflammation and retaining the intestinal 
barrier in SAP. 
3.5.8.3. Management of metabolic abnormalities:100 
Decrease in the levels of serum calcium is noted in AP and affects 
the prognosis of the disease if the level is < 7.5 mg/dl and hence 
administration of calcium at slow rate is considered. 
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AP itself can lead to hyperlipidemia and vice versa, so therapy 
should not be started for hyperlipidemia during an attack of AP. Re-
evaluation of hyperlipidemia after the recovery from an episode of AP 
must be done and then therapy can be considered. 
3.5.8.4. Inhibition of enzymes, secretion and inflammation:100 
Gabexate mesilate, a protease inhibitor was the first agent tried in 
humans to inhibit the pancreatic enzymes. Studies conducted with this 
drug have shown benefit which was not significant statistically. Gabexate 
showed to reduce the complications of AP by 30 %. 
Somatostatin and octreotide, the inhibitors of pancreatic secretion 
underwent various clinical trials and a meta-analysis showed that there 
was a reduction in the mortality which was statistically significant with 
somatostatin but not with octreotide which was not statistically 
significant. 
3.5.8.5. Nutrition: 
Nutrition to the patient with AP can be administered either by 
enteral route or parenteral route. Nasojejunal feeding is recommended 
during the episode of AP which helps in early initiation of oral intake and 
also improves the outcome of severe disease.100 
Enteral nutrition is considered to be the ideal route for 
administering nutrition as it provides rest to the pancreas. The wide range 
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of advantages of enteral nutrition over parenteral nutrition includes good 
glycemic control, decrease in the complications due to infection, 
reduction in the need for surgery and decrease in the mortality.102 
The ideal site of enteral administration is to place the tube by 
nasojejunal and nasogastric route.102 Even though traditional method is to 
start oral feed with low-fat diet when the patient is capable of taking oral 
feeds, evidence states that low-fat diet will not affect the recovery of the 
patient.100 
The enteral formulations that are available for administration of 
nutrition in AP are classified broadly into elemental formulation which 
includes amino acids, oligopeptides, maltodexrtrins and medium- and 
long-chain triglycerides.102  
Polymeric formulation includes nonhydrolyzed proteins, 
maltodextrins, oligofructosaccharides and long-chain triglycerides.102 
Immune enhancing formulation includes glutamine, arginine, 
omega-3 fatty acids, probiotics and fibre-enriched formulations which are 
hypothesized to modulate the immune system.102 
3.5.9. Complications:89 
  Complications due to AP are basically classified into local and 
systemic complications.  
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  Local complications of AP are pancreatic necrosis that may be 
sterile or infected, walled-off necrosis, pancreatic pseudocyst, collection of 
pancreatic fluid, pancreatic duct disruption, pancreatic ascites, involvement 
of contiguous organs, thrombosis of portal and splenic veins, pancreatic 
enteric fistula, bowel infarction and obstructive jaundice. 
  Systemic complications due to AP include pleural effusion, 
atelectasis, mediastinal fluid, pneumonitis, acute respiratory distress 
syndrome and hypoxemia. Cardiovascular complications include pericardial 
effusion, hypotension, hypovolemia and non specific ST-T changes in 
electrocardiogram suggestive of myocardial infarction. Hematological 
complications include disseminated intravascular coagulation, GI 
complications include peptic ulcer disease, gastritis due to erosion, portal 
and spleenic vein thrombosis and portal variceal hemorrhage. Renal 
complications include oliguria, azotemia, renal artery and vein thrombosis 
and acute tubular necrosis. 
3.5.10. Prognosis: 
  Imaging techniques play a major role in the prediction of prognosis 
of AP.103  
The mortality due to severe AP is 15% to 30% and mild 
pancreatitis is 0% to 1% which is mainly due to organ failure.104 The chance 
of secondary infection that occurs 3 to 4 weeks after the occurrence of 
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necrotizing pancreatitis is around 30% and its mortality goes up to 100% if 
left untreated.104  
Around 50% of deaths due to AP occur during the first seven days 
of an attack. The proportion of the survivors during the first week of the 
disease takes a sequence of clinically worst prognosis of pancreatic or 
peripancreatic necrosis. This can lead to secondary infection causing sepsis 
and multi organ dysfunction syndrome and finally leads to death of the 
remaining survivors.105 
The prognosis of mild case of AP is good as the recovery is 
complete in almost all the cases.105 
Cetinkaya et al.106 in their study conducted on 102 patients with AP 
identified platelet ratio to be a worthy and newer test to predict the prognosis 
of AP. 
Fisic et al.107 conducted a study to evaluate a diagnostic test which 
is valuable to assess the severity and course of AP and confirmed that 
interleukin [IL]-6, IL-8, IL-10 and soluble receptor for tumor necrosis factor 
[sTNFr] on the day 1. CRP and elastase on third day is also a valuable 
predictor of AP. 
Nieminen A et al.108 who conducted a study on 163 patients with 
AP have proven that evaluation of the levels IL-6 and hepatocyte growth 
factor [HGF] at the time of admission can predict the prognosis of severe 
AP. These markers are also similar to that of CRP, creatinine and calcium 
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levels. Estimating the levels of IL-8, HGF and granulocyte colony 
stimulating factor [G-CSF] at the time of admission can also be used as 
predictors of severe AP without signs of organ dysfunction. 
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4. Methodology: 
A prospective study was conducted on 71 patients in the Department of 
Pharmacology in collaboration with the Department of General Medicine, Sree 
Mookambika Institute of Medical Sciences [SMIMS], Kulasekharam, 
Kanyakumari District, Tamil Nadu for a period of one year from June 2014. The 
study protocol was approved by Institutional Human Ethics Committee [IHEC] 
[Ref No. SMIMS/IHEC/2013/C/13] and was submitted online to the Clinical 
Trial Registry - India [CTRI] [http://ctri.nic.in/clinicaltrials/login.php] and 
registered [CTRI/2014/07/004714 dated 04/07/2014]. 
4.1. Inclusion and Exclusion Criteria: 
 The criteria for inclusion of patients in the study were hyperlipidemic 
patients with total cholesterol [200 to 500 mg/dl], triglycerides [150 to 600 
mg/dl], low density lipoprotein [100 to 400 mg/dl], high density lipoprotein [<55 
mg/dl], very low density lipoprotein [10 to 33 mg/dl] of both sex between the 
age of 20-60 years. Alcoholic patients with family history of pancreatitis, 
pancreatic cancer, diabetes, hypertension, who had undergone Endoscopic 
Retrograde Cholangiopancreatography [ERCP], renal failure, drug intake 
pregnant and lactating women were excluded from the study. 
4.2. Parameters: 
The parameters that were observed during the study were serum lipase in 
U/L and random blood sugar [RBS] in mg/dl. 
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4.3. Procedure: 
The study was done in the General Medicine outpatient clinic of SMIMS 
hospital and 71 patients who were willing to participate in the study after 
satisfying the inclusion and exclusion criteria were included in the study. The 
patients were explained about the study and the procedure in detail and written 
informed consent was obtained from them before enrolling in the study.  
After the consenting process, each patient was taken to the central 
laboratory, and 3 ml of venous blood was collected by using 5 ml sterile 
disposable syringe by the normal phlebotomy procedure. The collected blood 
was then transferred to the test tube containing clot activator and was allowed to 
stay for 20 minutes [mins] or till the blood clotted. 
Image 1. Blood sample collected in clot activator tube 
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Image 2. Clotted blood in clot activator tube after 20 minutes 
 
The clotted blood was then centrifuged at the speed of 2500 rotations per 
minute [rpm] for 5 minutes [mins] using Remi R – 8C centrifuge manufactured 
by Remi Elektrotechnik Ltd. [Instrument Division], Vasai – 401 208, India, for 
the serum to get separated from the blood. The serum as a supernatant solution 
was collected using a 1000 micro liter [µl] pipette and transferred into 1.5 ml 
eppendorf safe-lock tube and used for analysis of serum lipase and blood glucose 
levels.  
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Image 3. Separated serum sample in eppendorf safe-lock tube 
 
 
 
 
 
 
 
 
 
 
 
 
Patients were initiated on statin therapy as advised by the physician for a 
period of three months. They were requested to come for review after 3 months. 
At the time of review, informed consent was again obtained for collection and    
3 ml venous blood was collected from each patient for estimation of serum lipase 
and blood glucose levels.  
The study procedure is schematically presented in Figure 5. 
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Figure 5. Schematic diagram of the study procedure. 
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4.4. Estimation of Serum Lipase: 
Estimation of serum lipase was done by kinetic method as described by 
Lipase color reagent manufactured by Biosystems S.A., Costa Brava 30, 
Barcelona [Spain], supplied by Star Diagnostic Supplies and Surgicals, 
Nagercoil and analyzed by using fully automated biochemistry analyser 
[BECKMAN COULTER Chemistry analyzer AU 480 manufactured by 
Beckman Coulter Mishima K.K. Beckman Coulter, Inc. 250 S Kraemer Blud, 
Brea, CA 92821, USA].  
4.5. Estimation of Blood Glucose: 
The estimation of blood glucose was done by using Glucose Monoreagent 
LR liquid reagent manufactured by GESAN production s.r.l. Italy, supplied by 
Star Diagnostic Supplies and Surgicals, Nagercoil and the analyzer used was 
Gesan Chem 200 Clinical chemistry autonalyzer [manufactured by Gesan, 71, 
Fiera dell’Eremita Street – 91021 Campobello di Mazara – Italy]. The estimation 
follows Colorimetric enzymatic glucose oxidase peroxidase [GOD-POD] method 
described by the manufacturer.  
4.6. Statistical analysis: 
The demographic data of patients age, height [Ht], weight [Wt], Body 
Mass Index [BMI], serum lipase in U/L and blood glucose in mg/dl were 
expressed in mean±standard deviation [mean±SD]. The distribution of sex was 
expressed in number [No.] and percentage [%].The data were entered into the 
Microsoft Office Excel 2007 for windows 7. 
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 GraphPad Instat version 3.06, 32 bit for Windows [GraphPad 
Software, San Diego, California USA] was used to analyze the data 
 For data with normal (Gaussian) distribution parametric test, paired 
‘t’ test was used to find out the statistical significance between the 
data before and after 3 months of statin therapy 
 For data with non-normal (Non-Gaussian) distribution non-
parametric test, Wilcoxon signed rank test was used to find out the 
statistical significance between the data before and after 3 months of 
statin therapy 
 P < 0.05 was considered as statistically significant 
 The results in table and bar diagrams were presented as Mean ± SD  
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5. Results:   
5.1. Study subjects: 
        Total number of participants recruited in this study was 71 after considering 
inclusion and exclusion criteria. The baseline parameters of the eligible 
participants were recorded before starting the statin therapy and the same were 
repeated after 3 months of statin therapy. 
The baseline characteristics of the study subjects are depicted in Table 4.  
5.2. Assessment of changes in serum lipase levels in all participants of the   
          study: 
        In this study, the serum lipase levels were significantly increased after 3 
months of statin therapy when compared to the baseline values [P<0.0001]. The 
changes in serum lipase levels before and after 3 months of statin therapy has 
been shown in figure 6.  
5.3. Assessment of changes in blood glucose levels in all participants of the     
          study: 
        The changes in blood glucose levels before and after 3 months of statin 
therapy has been illustrated in figure 7. There was statistical significant rise in 
blood glucose levels after 3 months of statin therapy when compared to the 
baseline values [P<0.0005]. 
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5.4. Assessment of changes in serum lipase levels in male participants: 
        In this study, the serum lipase was increased after 3 months of statin therapy 
when compared to the baseline values. However this was not found statistically 
significant when compared to the baseline values [P>0.05]. The changes in 
serum lipase levels before and after 3 months of statin therapy in male 
participants has been delineated in figure 8.  
5.5. Assessment of changes in blood glucose levels in male participants: 
      The study showed increase in blood glucose levels after 3 months of statin 
therapy when compared to the baseline values. However this was not found 
statistically significant when compared to the baseline values [P>0.05]. The 
changes in blood glucose levels before and after 3 months of statin therapy in 
male participants has been represented in figure 9.  
5.6. Assessment of changes in serum lipase levels in female participants: 
        The changes in serum lipase levels before and after 3 months of statin 
therapy in female participants has been depicted in figure 10. The study showed 
statistically significant increase in serum lipase levels after 3 months of statin 
therapy when compared to the baseline values [P<0.0001].  
5.7. Assessment of changes in blood glucose levels in female participants: 
      The changes in blood glucose levels before and after 3 months of statin 
therapy in female participants has been illustrated in figure 11. The study showed 
statistically significant increase in blood glucose levels after 3 months of statin 
therapy when compared to the baseline values [P<0.004]. 
  Results 
Page | 75  
 
 
 
 
 
 
 
  
 Mean±SD 
Age (in Years) 41.59±8.71 
Male (%) 35(49.3)* 
Female (%) 36(50.7)* 
BMI 26.56±2.41 
Serum lipase (Units/L) 25.54±4.96 
Blood glucose (mg/dl) 104.56±8.38 
Total cholesterol (mg/dl) 255.20±34.01 
Triglycerides (mg/dl) 192.73±44.78 
LDL (mg/dl) 140.11±32.82 
HDL (mg/dl) 36.46±5.46 
VLDL (mg/dl) 38.80±8.85 
 
Table 4: Baseline characteristics of the study subjects 
Data are represented as Mean ± SD 
*Values are expressed in number (percentage) [%] 
 n = 71  
BMI:                 Body Mass Index 
L:                      Litres 
mg:                   milligrams 
dl:                     decilitres 
LDL:                 Low Density Lipoproteins 
HDL:                High Density Lipoproteins 
VLDL:              Very Low Density Lipoproteins 
 
 
BMI was calculated by using the following formula: 
BMI= Weight (Kg)/Height in meter square 
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Figure 6. Bar diagram depicting the serum lipase [Units/Litre] levels  
                 before and after 3 months of statins therapy in  
                 hypercholesteremic patients 
Data are represented as Mean ± SD 
 n = 71 
*P < 0.0001 when compared to the values before the start of statins 
Data are analysed by using non-parametric Wilcoxon signed rank test 
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Figure 7. Bar diagram depicting the blood glucose [mg/dl] levels before and  
                 after 3 months of statins therapy in hypercholesteremic patients 
Data are represented as Mean ± SD 
 n = 71 
*P < 0.0005 when compared to the values before the start of statins 
Data are analysed by using non-parametric Wilcoxon signed rank test 
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Data are represented as Mean ± SD 
 n = 35 [Male hypercholesteremic patients] 
*P > 0.05 when compared to the values before the start of statins 
therapy 
Data are analyzed by using paired ‘t’ test 
Figure 8. Bar diagram depicting the serum lipase [Units/Litre] levels before and  
                  after 3 months of statins therapy in male hypercholesteremic patients 
* 
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Figure 9. Bar diagram depicting the blood glucose [mg/dl] levels before and  
                  after 3 months of statins therapy in male hypercholesteremic  
                  patients 
Data are represented as Mean ± SD 
 n = 35 [Male hypercholesteremic patients] 
*P > 0.05 when compared to the values before the start of statins therapy 
 
Data are analyzed by using paired ‘t’ test 
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Figure 10. Bar diagram depicting the serum lipase [Units/Litre] levels  
                     before and after 3 months of statins therapy in female  
                     hypercholesteremic patients 
Data are represented as Mean ± SD 
 n = 36 [Female hypercholesteremic patients] 
*P < 0.0001 when compared to the values before the start of statins 
Data are analyzed by using non-parametric Wilcoxon signed rank test 
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Figure 11. Bar diagram depicting the blood glucose [mg/dl] levels before and  
                  after 3 months of statins therapy in female hypercholesteremic  
                  patients 
Data are represented as Mean ± SD 
 n = 36 [Female hypercholesteremic patients] 
*P < 0.004 when compared to the values before the start of statins therapy 
 
Data are analyzed by using non-parametric Wilcoxon signed rank test 
* 
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6. Discussion: 
This study was minted to explore the effect of statin therapy on serum 
lipase and blood glucose levels in hyperlipidemic patients who have attended 
the outpatient department of the teaching tertiary care hospital in 
Kanyakumari District. This study included a total of 71 participants, each 
diagnosed to be a new case of hyperlipidemia and initiated on statin therapy. 
Our study revealed that there was a statistically significant increase in 
both the levels of serum lipase and blood glucose after 3 months of statin 
therapy in hyperlipidemic patients. 
In contrary to our study, various animal and human studies have shown 
that statins do not have negative impact on the pancreas.  
Almeida et al.109 conducted a study on male wistar rats have shown to 
decrease the cytokines due to inflammation and activation of neutrophils in 
lungs after inducing Acute Pancreatitis [AP] with cerulin or taurocholate. In a 
study conducted by Choi et al.110 on cholecystokinin induced pancreatitis in 
male wistar rats which were pretreated with statin have shown that statins 
ameliorated the severity of pancreatitis.  
Wei et al.111 conducted an experimental study on male wistar rats to 
evaluate the effect of pravastatin on chronic pancreatitis. The above study 
showed, reduction of pancreatic inflammation. Mita et al.112 conducted an 
open-label, crossover study on 24 patients which was have shown that 
pravastatin improved the pancreatic cell function. 
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The above studies were controversial to the results that have been 
obtained from our study which has shown that statin therapy has significantly 
increased the serum lipase levels. This result which is contentious to the 
above study may be due to the use of male wistar rats only, where as our 
study was conducted on humans of both sexes.  
Prajapati et al.92 reported a case of AP in a 58 year old male patient due to 
atorvastatin therapy which was confirmed by CT and elevated serum lipase 
level and the patient recovered within 10 days of stopping the drug. 
Chitanaboina et al.10 and Singh et al.11 reported cases of rosuvastatin induced 
AP which were confirmed by elevated serum lipase level and CT.  
There were also case reports of acute pancreatitis due to simvastatin12,14,91 
and pravastatin9,13, which were confirmed by clinical examination and 
laboratory investigations.12,14,91 
Our study results were correlating with the various case reports9-14,91,92 as 
discussed above, which has shown that statin therapy can lead to rise in 
serum lipase levels.   
In this study, it was revealed that there was significant rise in blood 
glucose in the statin treated patients. 
Shah et al.113 in their study concluded that statin therapy leads to the risk 
of developing diabetes mellitus. A study conducted by Swerdlow et al.114 
revealed that patients having 3-hydroxy-3-methylglutaryl CoA reductase 
[HMGCR] gene with single nucleotide polymorphisms is associated with 
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increased body weight and risk of type 2 diabetes mellitus which was due to 
the insulin resistance with statin. 
Aimen et al.115 study proved that the possibility of developing new onset 
diabetes was increased with statin therapy and had a strong correlation with 
simvastatin, rosuvastatin and atorvastatin. Barylski et al.116 in their study had 
shown that statins were useful in diabetic patients, but the risk of new onset 
diabetes was increased that overweighed the cardiovascular benefit. 
Dasgupta117 in their study had concluded that there was a significant risk of 
developing new-onset diabetes.  
Dormuth et al.118 done a study on patients who were on statin therapy for 
secondary prevention of cardiovascular disease had concluded that use of 
statin having higher potency was moderately associated with a risk of 
developing new-onset diabetes.  
Macedo et al.119 concluded in their study that the use of statin had an 
association with a higher risk of developing type 2 DM and the risk was 
relatively higher in non hypertensive people. Kanda et al.120 in his study on 
male Sprague Dawley rats had shown that atorvastatin significantly increased 
blood glucose level in oral glucose tolerance test [OGTT].  
Our study results also have revealed that blood glucose level was 
significantly increased which was similar to the studies113-120 conducted by 
various researchers around the world. 
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Satoh et al.121 in his study on GK rats concluded that statin administration 
did neither improved the diabetes nor exaggerated the oral glucose tolerance 
test.  
Otani et al.122 conducted a study on rats and concluded that pravastatin 
therapy for longer duration had improved the status of diabetes mellitus and 
pancreatic fibrosis which was due to anti-oxidative and anti-fibrotic 
properties. This also concluded that stopping the administration of pravastatin 
had shown to revoke the beneficial effects and expedite DM and fibrosis of 
pancreas. 
Marchand et al.123 study result showed that the mass of the β-cell has 
expanded and raised the plasticity of islets in atorvastatin treated rats. Chen et 
al.124 concluded in their study done on obese C57BL/6J mice that treatment 
with atorvastatin had increased the proliferation of pancreas and decreased 
the endoplasmic-reticulum stress on pancreas. 
Studies conducted by various researchers121-124 were not correlating with 
the results obtained from our current study. This could be due to the variation 
in the pharmacodynamic response of atorvastatin or rosuvastatin between 
animals and humans. Further, the participants in this study were on either 
atorvastatin or rosuvastatin, the effect of other members of statin group could 
not be evaluated. 
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United States Food and Drug Administration [USFDA] in 2012 stated the 
safety profile of statin that it can increase glycosylated haemoglobin and 
fasting blood glucose level.125  
In this study, we assume that the negative impact of statin on pancreas 
leading to increased serum lipase levels would have been the cuase for raise 
in blood glucose levels.  
The strength of this current study are; the study was registered in the 
Clinical Trial Registry-India, estimation of serum lipase and blood glucose 
levels were done using the same kit with same analyzer for all the study 
participants. Sample size was calculated using the appropriate formula by 
using the previous study on the prevalence of dyslipidemia126 conducted in 
the southern part of Kerala which was located very close to the study site that 
reflects the status of hyperlipidemia. In this study, the treatment compliance 
was assessed by pill count method and factors that can cause AP are 
excluded. 
The shortcomings of this current study were, other investigation tools like 
CT, USG and estimation of serum amylase were not done. Hence further 
study has to be considered on large population to extract a valid data about 
the effect of statin therapy on pancreas. 
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7. Conclusion: 
Atorvastatin or rosuvastatin therapy for 3 months in newly diagnosed 
hyperlipidemic patients has significantly increased the serum lipase and 
blood glucose levels. 
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8. Summary: 
Hyperlipidemia is due to an increase in the levels of various 
lipoproteins namely cholesterol, triglycerides, low density lipoproteins, high 
density lipoproteins and very low density lipoproteins and is an important 
factor that can lead to non-communicable disease like coronary artery disease 
and cerebrovascular disease in India.1 The prevalence of dyslipidemia was 
37.5% in the age group of 15-64 years and 62% in young males working in 
industry.2 Hence it is necessary to screen for hyperlipidemia above the age of 
20 years.28 
Statins are found to be the most effective and well tolerated drug to 
reduce the lipid levels.6,7 These drugs act by inhibiting the formation of 
mevalonate from 3 Hydroxy-3-methyl glutaryl Coenzyme A.6,7 Various 
members of this group of drugs include atorvastatin, rosuvastatin, fluvastatin, 
lovastatin, pitavastatin, simvastatin and pravastatin.6-8 Except atorvastatin and 
rosuvastatin all other statins should be administered at night time due to the 
shorter duration of action.6 
Acute pancreatitis [AP] is an inflammatory condition of the pancreatic 
cell which clinically presents with abdominal pain, vomiting and fever and 
with the annual prevalence of 13-45/100000 persons.85,87,93,94 The mortality is 
around 2-9% with AP.88 The commonest causes of AP include gall stones, 
alcohol, endoscopic retrograde Colangiopancreatography, 
hypertriglyceridemia and drugs.89 Apart from theses causes, various case 
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reports states that statin also could cause AP.9-14,91,92 Estimation of serum 
lipase, amylase, blood glucose levels and radiological investigations plays a 
major role in diagnosing AP.95  
Pancreatitis is found to be the cause for hyperglycemia and elevation 
of serum lipase and amylase by 3 fold than the normal levels are the 
diagnostic criteria for AP.75,85 
There were no studies done in this part of Tamil Nadu to prove that 
statin therapy can increase serum lipase and blood glucose levels. Hence this 
study was designed to know the effect of statin therapy on serum lipase and 
blood glucose levels in hyperlipidemic patients who visit the teaching tertiary 
care hospital in Kanyakumari District [Tamil Nadu]. 
This was a prospective study, which enrolled 71 study participants, 
newly diagnosed as hyperlipidemia. Among the study participants, 35 were 
males and 36 were females. After getting the approval from Institutional 
Human Ethics Committee [IHEC], written informed consent was obtained 
and the patients were enrolled into the study. Baseline serum lipase and blood 
glucose levels were estimated in them and statin therapy was initiated. Study 
participants were advised to come for follow up after 3 months and serum 
lipase and blood glucose levels were estimated. 
In this study, there was statistically significant rise in both serum 
lipase and blood glucose levels in participants after 3 months of statin therapy 
when compared to their baseline values. This study also showed that there 
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was significant increase in the serum lipase and blood glucose levels in 
female participants after 3 months of statin therapy, when compared to their 
baseline values. However, there was elevation in the levels of serum lipase 
and blood glucose in male study participants after 3 months of statin therapy, 
when compared to their baseline values, but it was found to be statistically 
insignificant.  
These study findings were comparable to the previous studies reported 
in the literature.9-14,91,92 However the results obtained in this study was 
controversial to some of the findings obtained from other studies.109-112,122-124 
This study excluded the study participants with factors which predisposed to 
the elevation of serum lipase and blood glucose levels. The pitfall of this 
study is the lack of CT scanning to confirm the diagnosis of acute 
pancreatitis.  
The study concludes that there is a significant increase in the serum 
lipase and blood glucose levels after 3 months of statin therapy in 
hyperlipidemic patients. However, further long term clinical trials with larger 
sample size will be helpful to explore the effect of statin therapy on pancreas. 
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precautions and the information about how this project will be carried out. It is important that 
you read and understand the contents of the form carefully. This form may contain certain 
scientific terms and hence, if you have any doubts or if you want more information, you are 
free to ask the study personnel or the contact person mentioned below before you give your 
consent and also at any time during the entire course of the project. 
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4. Institute         :   Sree Mookambika Institute of Medical Sciences,              
             Kulasekaram, Kanyakumari District,TamilNadu. 
5. Title of the study :  
Effect of Statin Therapy on Serum Lipase and Blood Glucose Levels in 
Patients with Hyperlipidemia. 
6. Background Information :  
Abnormality in the lipid metabolism and plasma lipoproteins causes hyperlipidemia 
and statins are the commonly prescribed drugs for the treatment of hyperlipidemia. Even 
though no adverse effect of acute pancreatitis due to statin therapy have been mentioned 
in standard textbooks, there are few case reports of acute pancreatitis with statin therapy. 
Serum lipase and blood glucose levels are the diagnostic tools in acute pancreatitis.  
7. Aims and objectives :  
 To study the Effect of Statin Therapy on Serum Lipase and Blood Glucose Levels in 
Patients with Hyperlipidemia. 
8. Scientific justification of the study :  
 As there were case reports on statin induced acute pancreatitis and no standard 
textbooks states acute pancreatitis as an adverse effect of statins therapy, which is a 
frequently prescribed drug for the management of hyperlipidemia. It is necessary to do a 
study on Serum lipase and blood glucose levels for the patient on statin therapy.  
9. Procedure for the study :  
   Under strict aseptic precautions 3 ml of venous blood will be collected from 
you in a plain sterile test tube for lipid profile estimation. If you are diagnosed to be a 
hyperlipidemic, written informed consent will be obtained from you and then evaluated 
for serum lipase and blood glucose levels before statin therapy. Then you will be advised 
to take statin for the management of hyperlipidemia. After the period of 3 months you 
will be advised to review at the General Medicine OPD for evaluation of lipid profile, 
  Consent Form 
 
serum lipase and blood glucose levels with 3 ml of blood and all the readings will be 
noted. You will not have to spend additional expenses for the study related investigations. 
10. Expected risk for the participants :  
i. Risk of allergic reaction to drug. 
ii. Pain at the site of drawing the blood. 
iii. Thrombophlebitis – very rare. 
iv. Hepatotoxicity.  
v. Myalgia. 
vi. Headache.  
11. Expected benefits of research for the participants :  
  You may not have any personal gain because of this study but it may be beneficial to 
the society and medical fraternity in the future. 
12. Maintenance of Confidentiality  : Yes.  
13. Why have I been chosen to be in this study  : Hyperlipidemia. 
14. How many people will be in the study   : 71 
15. Agreement of compensation to the participants :  
  Compensated by principal investigator as per the suggestions of IHEC. 
16. Anticipated prorated payment, if any, to the participant’s in the study : No. 
17.  Can I withdraw from the study at any time during the study period? :Yes. 
18. If there is any new findings/ information, would I be informed? : Yes. 
19. Expected duration of the participant’s participation in the study : 3 months. 
20. Any other pertinent information : No. 
21. Whom do I contact for further information? 
For any study related queries, you are free to contact 
Dr. Prathab Asir. A, 
I year Post Graduate, Department of Pharmacology, 
Sree Mookambika Institute of Medical Sciences, 
Kulasekharam – 629 161, 
Mobile No. : +91-9443490137 
Email ID : asirprathap@yahoo.com 
 
Place : Kulasekharam,    Signature of the Principal Investigator 
Date :                                                                               
 
Signature of the Participant 
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CONSENT FORM 
PART 2 OF 2 
PARTICIPANTS CONSENT FORM 
 The details of the study have been explained to me in writing. I am aware that the 
results of the study may not be directly beneficial to me but it will help in the advancement of 
medical sciences. I confirm that I have understood the study and had the opportunity to ask 
questions. I understand that my participation in the study is voluntary and that I am free to 
withdraw from the study at any time, without giving any reason and that it will not interfere 
with the normal course of treatment. I agree to make use of any data or results that arise from 
this study provided such a use is only for scientific purpose(s). I have been given an 
information sheet giving details of the study. I fully consent to participate in the study with 
the title “Effect of Statin Therapy on Serum Lipase and Blood Glucose Levels in Patients 
with Hyperlipidemia”. 
 
Serial No. :       O.P. No. : 
 
Name of the Participant : 
 
Address of the Participant ; 
 
 
 
 
 
Contact number of the participant : 
 
 
 
Signature/ Thumb impression of the participant 
Witnesses : 
 
1. 
 
 
2. 
 
 
Place :Kulasekharam 
Date : 
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SREE MOOKAMBIKA INSTITUTE OF MEDICAL SCIENCES 
Kulasekharam, Kanyakumari District, Tamil Nadu, India – 629161 
Department of Pharmacology 
Title of the Study : Effect of Statin Therapy on Serum Lipase and Blood Glucose 
Levels in Patients with Hyperlipidemia 
 
 
 
Subject number:   O.P. No. :                  I.P.No.:   Date: 
 
 Name:  
 
Age:      Sex: M / F  
 
Ht.:      Wt.:                         BMI: 
 
Occupation:       
 
Address with contact number: 
 
Diagnosis: 
 
Family History: Diabetes Mellitus/ Hypertension/ Hyperlipidemia 
 
Any other concurrent medication used? Yes / No. (If yes then details) 
 
Prescription details 
S.No Non-proprietary 
name 
Brand 
name 
Company 
name 
Form Dose Route Frequency 
        
        
        
 
Parameters: 
Statin 
therapy  
Date of 
visit 
Serum 
Lipase 
(U/L) 
B. 
Glucose 
mg/dl 
TCH 
mg/dl 
 
TGL 
mg/dl 
 
LDL 
mg/dl 
 
HDL 
mg/dl 
VLDL 
mg/dl 
Before          
After          
 
 
Signature of the Principal Investigator 
CASE RECORD FORM 
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  Images 
 
Image 4. Kit used for serum lipase estimation [Biosystems S.A., Spain] 
  Images 
 
Image 5. Brochure of serum lipase provided by the kit manufacturer  
               [Biosystems Reagents and Instruments] 
  Images 
 
Image 6. Instrument used for estimation of serum lipase [Beckman Coulter  
                 Chemistry analyzer AU 480] 
 
  Images 
 
Image 7. Kit used for estimation of blood glucose [Glucose Monoreagent LR  
                  liquid reagent, Gesan production s.r.l. Italy.] 
 
  Images 
 
Image 8. Brochure of blood glucose monoreagent provided by the kit  
                 manufacturer [Gesan Production s.r.l] 
 
  Images 
 
Image 9. Instrument used for estimation of Blood glucose [Gesan Chem 200  
                  clinical chemistry autoanalyzer] 
 
  Abbreviation 
ABBREVIATIONS List of abbreviations 
% Percentage 
µl Microlitre 
ABG Arterial blood gas 
ADRs Adverse drug reactions 
ALT Alanine aminotransferase 
AMY Amylase 
AP Acute pancreatitis 
APACHE Acute physiology and chronic health evaluation 
APOE Apolipoprotein E 
ARM Age related maculopathy 
AST Aspartate transaminase 
ATP Adenosine triphosphate 
ATP III Adult Treatment Panel III 
BISAP Bedside index of severity in acute pancreatitis 
BMI Body mass index 
BPH Benign prostatic hyperplasia 
BSI Blood stream infection 
BUN Blood urea nitrogen 
CAD Coronary artery disease 
CETP Cholesterol esterase transfer protein 
CKD Chronic kidney disease 
CoA Coenzyme A 
CRP C-Reactive Protein 
CT Computerized tomomgraphy 
CTRI Clinical Trial Registry - India 
CTSI Computerized tomomgraphy severity index 
CVD Cerebrovascular disease 
CYP Cytochrome P 
Da Dalton 
DHA Docosahexaenoic acid 
DKA Diabetic keto acidosis 
DM Diabetes mellitus 
EPA Eicosapentaenoic acid 
ERCP Endoscopic Retrograde Cholangio Pancreatography 
gms Grams 
G-CSF Granulocyte colony stimulating factor 
GI Gastrointestinal 
H Hour 
HbA1C Glycosylated hemoglobin 
HDL High-density lipoprotein 
  Abbreviation 
HES Hydroxyethyl starch 
HGF Hepatocyte growth factor 
HMG-CoA 3-Hydroxy-3-methyl glutaryl coenzyme A 
HMGCR 3-Hydroxy-3-methyl glutaryl coenzyme A reductase 
HOMA-IR Homeostatic model assessment-insulin resistance 
HONK Hyper osmolar non ketotic coma 
hs-CRP High-sensitivity C-reactive protein 
Ht Height 
ICAM Inter cellular adhesion molecule 
IHEC Institutional Human Ethics Committee 
IL Interleukin 
IPE Icosapent ethyl 
IV Intravenously 
kg Kilogram 
LCAT Lecithin cholesterol acyl transferase 
LDL Low-density lipoproteins 
LDLR low-density lipoprotein receptor 
LPL Lipoprotein lipase 
LPS Lipase 
MDCT Multi detector computerized tomography 
mg/dl Milligram per decilitre 
mins Minutes 
ml Millilitre 
MMP Metalloproteinases 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetra hydropyridine 
MRI Magnetic resonance imaging 
NADH Nicotinamide dinucleotide hydride 
NCEP National Cholesterol Education Programme 
NCMH National Commission on Macroeconomics and Health 
No. Number 
NS Normal saline 
NSAID Non steroidal anti-inflammatory drug 
OATP Organic anion transporter 
OATP1B1 Organic anion transporting polypeptide 1 B1 
OCP Oral contraceptive pill 
OGTT Oral glucose tolerance test 
PAI-1 Plasminogen activator inhibitor-1 
PAP Pancreatitis associated protein 
PLA2 Phospholipase A2 
PVD Peripheral vascular disease 
RBS Random blood sugar 
RCT Randomized clinical trial 
rpm Rotations per minute 
  Abbreviation 
SAP Severe acute pancreatitis 
SD Standard deviation 
SLE Systemic lupus erythromatosis 
SMIMS Sree Mookambika Institute of Medical Sciences 
SNP Single nucleotide polymorphism 
SREBPs Sterol Regulatory Element-Binding Proteins 
TCH Total cholesterol 
TGL Triglycerides 
TNF-α Tumor necrosis factor alpha 
TTP Thrombocytopenic purpura 
U/L Unit per litre 
USFDA United States Food and Drug Administration 
USG Ultrasonography 
VF Ventricular Fibrillation 
VIP Vasoactive intestinal polypeptide 
VLDL Very low density lipoprotein 
VT Ventricular tachycardia 
WBC White blood cell 
WHO-UMC World Health Organization-Uppsala Monitoring Centre 
Wt Weight 
α Alpha 
β Beta 
δ Delta 
μl Micro litre 
 
